Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03084042
Other study ID # UESTC-neuSCAN-23
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 2016
Est. completion date June 2019

Study information

Verified date October 2018
Source University of Electronic Science and Technology of China
Contact Benjamin Becker, Dr.
Email ben_becker@gmx.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to 1) examine common and specific emotional and cognitive dysfunctions between Major Depression and generalized anxiety disorder; 2) Examine emotional and cognitive dysfunctions between the two disorders and healthy controls; 3) Examine the biomarkers predicting successful therapy or not.


Recruitment information / eligibility

Status Recruiting
Enrollment 105
Est. completion date June 2019
Est. primary completion date December 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- GAD:

1. Diagnosis of Generalized Anxiety Disorder (GAD) according to DSM V criteria in a structured clinical interview for DSM-V Axis I disorders (SCID I; APA, 2014) and a confirmatory clinical interview

2. Duration of the current episode > 3 weeks

- MDD:

1. Diagnosis of current major depressive disorder in a structured clinical interview for DSM-V Axis I disorders (SCID I; APA, 2014) and a confirmatory clinical interview

2. Duration of the current episode > 4 weeks

Exclusion Criteria:

- GAD: diagnosis of any other psychiatric Axis I disorder (except GAD) as a principal diagnosis within the past six months

- MDD: diagnosis of any other psychiatric Axis I disorder (except MDD) as a principal diagnosis within the past six months

Study Design


Intervention

Device:
fMRI


Locations

Country Name City State
China School of Life Science and Technology, University of Electronic Science and Technology of China Chendu Sichuan

Sponsors (3)

Lead Sponsor Collaborator
University of Electronic Science and Technology of China Sichuan Provincial People's Hospital, The Fourth People's Hospital of Chengdu

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Brain activity in the emotional and cognitive core regions of the brain as assessed by fMRI fMRI based indices during emotional face processing 1 hour (assessed at study inclusion)
Primary Brain activity in the emotional and cognitive core regions of the brain as assessed by fMRI fMRI based indices during empathy processing 1 hour (assessed at study inclusion)
Primary Brain activity in the emotional and cognitive core regions of the brain as assessed by fMRI fMRI based indices during working memory 1 hour (assessed at study inclusion)
Secondary Behavioral performance during the fMRI: face processing Accuracy during face processing 1 hour (assessed at study inclusion)
Secondary Behavioral performance during the fMRI: empathy reactivity Empathy in response to empathy inducing pictures (rated on Likert scale) 1 hour (assessed at study inclusion)
Secondary Behavioral performance during the fMRI: working memory Working memory performance during fMRI 1 hour (assessed at study inclusion)
Secondary Cognitive performance at study inclusion Executive functions as assessed via computerized tests (CANTAB) 1 hour (assessed at study inclusion)
Secondary Symptom improvement after 3 months: depression Symptoms of depression will be assessed using validated clinical scales (e.g. BDI) 3 months
Secondary Symptom improvement after 3 months: anxiety Symptoms of generalized anxiety will be assessed using validated clinical scales (e.g. Penn State Worry Questionnaire) 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A